Rudolf Foundation Clinic Report issue

Foundation Phase 3

Organization Overview

First Clinical Trial
2005
NCT00532142
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Alternative names

Department of Ophthalmology, Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery, Rudolf Foundation Clinic

Active Ingredients

Drugs in Phase 3 Trials (3)

ranibizumab (lucentis) (1 trial)

retaine (1 trial)

triamcinolone (kenalog) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Edema (Phase 3)

Macular Degeneration (Phase 3)

Macular Edema (Phase 3)

Retinal Vein Occlusion (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3